Ropinirol: A novel dopamine agonist for treatment of Parkinson's disease;Ropinirol: Un agonista dopaminergico novedoso en el tratamiento de la enfermedad de Parkinson

Neurologia

Volumn 12, Issue 8, 1997, Pages 354-361

  Gimenez Roldan S ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Dopamine agonists; Parkinson's disease; Ropinirol

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE; SEROTONIN RECEPTOR; INDOLE DERIVATIVE;

AKINESIA; DRUG EFFICACY; DRUG STRUCTURE; DYSKINESIA; HUMAN; HYPOTENSION; NAUSEA; PARKINSON DISEASE; RETROPERITONEAL FIBROSIS; REVIEW; STEREOSPECIFICITY; VOMITING;

DOPAMINE AGONISTS; HUMANS; INDOLES; PARKINSON DISEASE;

EID: 0031243410     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK. Treatment of parkinsonism with bromocriptine. Lancet 1974; 2: 1.355-1.356.
2. Lieberman A, Kupersmith M, Estey E, Goldstein M. Treatment of Parkinson's disease with bromocriptine. N Engl J Med 1976; 295: 1.400-1.404.
3. Lang AE, Quinn N, Brincat S, Marsden CD, Parkes JD. Pergolide in late-stage Parkinson's disease. Ann Neurol 1982; 12: 243-247.
4. Ahlskog JE, Muenter MD. Pergolide: long-term use in Parkinson's disease. Mayo Clin Proc 1988; 63: 979-987.
5. Obeso JA, Luquin MR, Martínez Lage JM. Lisuride oral en la enfermedad de Parkinson. Med Clin (Barc) 1985; 85: 307-312.
6. Wolters ECH, Tissingh G, Bergmans PLM, Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology 1995; 45 (Supl 3): 28-34.
7. Piccoli F, Ruggieri RM. Dopaminergic agonists in the treatment of Parkinson's disease. J Neural Transm 1995; 45 (Supl): 187-195.
8. King DB. The place of dopaminergic agonists in the treatment of Parkinson's disease: the view from the trenches. Can J Neurol Sci 1992; 19: 156-159.
9. Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ. Clinical trials of add-on medication in Parkinson's disease: efficacy versus usefulness. Parkinsonism & Relat Disord 1997; 3: 1-6.
10. Eden RJ, Costall B, Domeney AM, Gerrard PA, Harvey CA, Kelly ME et al. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav 1991; 38: 147-154.
11. Hubble JP, Koller WC, Cutler CR, Sramek JJ, Friedman J, Goetz C et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18: 338-347.
12. Graham JR, Suby HJ, LeCompte PR, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966; 274: 259-368.
13. Duvoisin RC. Digital vasospasm with bromocriptine. Lancet 1976; 1: 204.
14. Eisler T, Hall RP, Kalavar KAR, Calne DB. Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine. Neurology 1981; 31: 1.368-1.370.
15. Rinne UK. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet 1981; 1: 44.
16. LeWitt PA, Calne DB. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet 1981; 1: 44-45.
17. Demonet JF, Rostin M, Dueymes OM, Loulalen A, Montastruc JL, Rascol A. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol 1986; 9: 200-201.
18. Jimenez-Jiménez J, López Álvarez J, Sánchez Chapado M, Montera E, Miguel J, Sierra A et al. Retroperitoneal fibrosis in a patient with Parkinson's disease. Clin Neuropharmacol 1995; 18: 277-279.
19. Ward CD, Thompson J, Humby MD. Pleuropulmonary and retroperitoneal fibrosis associated with bromocriptine treatment. J Neurol Neurosurg Psychiatry 1987; 50: 1.706-1.797.
20. Saura J, Aguilar M, Alió J. Derrame pleural y pericarditis constrictiva secundaria al tratamiento con bromocriptina. Neurología 1991; 6: 331-333.
21. Dupont E, DeFine Olivarius B, Strong MJ. Bromocriptine induced collagenosis-like symptomatology in Parkinson's disease. Lancet 1982; 1: 850-851.
22. Quinn NP, Ring H, Honavär M, Marsden CD. Contractures of the extremities in parkinsonian subjects: a report of three cases with possible association with bromocriptine treatment. Clin Neuropharmacol 1988; 11: 268-277.
23. Strange PG. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease. Mov Disord 1993; 8: 263-270.
24. Stoessl AJ. Which dopamine receptor(s) do we need for motor function? Lessons from gene targeting and translation blockade. Parkinsonism & Relat Disord 1996; 2: 167-175.
25. Antonioni A, Ventobel P, Psylla M, Günther I, Maguire PR, Missimer J et al. Complementary positron emission tomography studies in the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995; 52: 1.183-1.190.
26. Ahlskog JE, Richelson E, Nelson A. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuation parkinsonian patients. Ann Neurol 1991; 30: 185-191.
27. 11C] raclopride. Mov Disord 1997; 12: 33-38.
28. Giménez-Roldán S, Mateo D. Discontinuation of prolonged bromocriptine therapy in Parkinson's disease patients with uncontrolled motor oscillations. Clin Neuropharmacol 1994; 17: 435-444.
29. Hubbard CA, Trugman JM. Reversal of reserpine-induced catalepsy by selective D and D2 agonists. Mov Disord 1993; 8: 473-478.
30. Emre M, Rinne UK, Rascol A, Lees A, Agid Y, Lataste X. Effects of a selective D partial agonist CY 208-243 in the novo patients with Parkinson's disease. Mov Disord 1992; 7: 239-243.
31. Tsui JKC, Wolters ECH, Peppard RF, Calne DB. A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease. Neurology 1989; 39: 856-858.
32. Temlett JA, Quinn NP, Jenner PG, Marsden CD, Poncher E, Bonnet AM et al. Antiparkinsonian activity of CY 208-243, a partial D1 agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov Disord 1989; 4: 261-265.
33. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-375.
34. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990; 13: 266-271.
35. Gerfen CR, Engber TM, Mahan LC, Sugel Z, Chase TN, Monsma FJ et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1.429-1.432.
36. Surmeier DJ, Reiner A, Levine MS, Ariano MA. Are neostriatal dopamine receptors colocalized? Trends Neurosci 1993; 16: 299-305.
37. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 1990; 13: 448-458.
38. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 1990; 40: 927-933.
39. Nutt JG. Levodopa-induced dyskinesia. Review, observations, and speculations. Neurology 1990; 40: 340-345.
40. Luquin MR, Laguna J, Obeso JA. Selective D2 receptor induces dyskinesias in parkinsonian monkeys. Ann Neurol 1992; 31: 551-554.
41. Marconi R, Lefebre-Caparros D, Bonnet AM, Vidailhet M, Duboix B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease. Phenomenology and pathophysiology. Mov Disord 1994; 9: 2-12.
42. Laitinen LV, Bergenheim T, Hariz ML. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76: 53-61.
43. Narabayashi H, Yokochi F, Nakajima Y. Levodopa-induced dyskinesia and thalamotomy. J Neurol Neurosurg Psychiatry 1984; 47: 831-839.
44. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989; 25: 523-526.
45. Boyce S, Clarke CE, Luquin R, Peggs D, Robertson RG, Mitchell IJ et al. Induction of chorea and dystonia in parkinsonian primates. Mov Disord 1990; 5: 3-7.
46. Giménez-Roldán S, Tolosa E, Burguera JA, Chacón J, Liano H, Forcadell F. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective, randomised study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 1997; 20: 67-76.
47. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist-induced dyskinesias in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990; 5: 100-108.
48. Chase TN, Metman V, Bravi D, Roberts JW, Sibley DR, Mouradian MM. Dopamine-receptor subtype selective agonists in the treatment of Parkinson's disease. Clin Neuropharmacol 1995; 18 (Supl 1): 207-215.
49. Pearce RKB, Banerji P, Jenner CD, Marsden CD. Effects of repeated treatment with L-Dopa, bromocriptine and ropinirole in drug naive MPTP-treated common marmosets. Br J Pharmacol 1996; 118 (Supl 37): 45.
50. Walsh FX, Stevens TJ, Langlais PJ, Bird ED. Dopamine and homovallinic acid concentrations in striatal and limbic regions of human brain. Ann Neurol 1982; 12: 52-55.
51. Melamed E, Zoldan J, Friedberg G, Goldberg-Stern F. An hallucinations in Parkinson's disease due to central serotonergic hyperactivity? Mov Disord 1993; 8: 407.
52. Zoldan J, Friedberg G, Liuneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a5-HT3 receptor antagonist. Neurology 1995; 45: 1.305-1.308.
53. Rascol O. A double-blind L-Dopa-controlled study of ropinirole in patients with early Parkinson's disease. Neurology 1996; 46 (Supl 2): 160.
54. Wheadon DE, Wilson-Lynch K, Gardiner D, Kredider MS. Ropinirole, a non-ergoline D2 agonist, is effective in early parkinsonian patients not reated with l-dopa. Mov Disord 1996; 11 (Supl 1): 601.
55. Korczyn AD. A double-blind study comparing ropinirole and bromocriptine in patients with early Parkinson's disease. Neurology 1996; 46 (Supl 2): 159.
56. Rascol O, Lees AJ, Senard J, Pirtosek Z, Brefel C, Montastruc JL et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996; 19: 234-245.
57. Brooks DJ, Torjanski N, Burn DJ. Ropinirol in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995; 45 (Supl): 231-238.
58. Kreider MS, Knox S, Gardiner D, Wheadon DE. A multicenter double-blind study of ropinirole as an adjunt to L-dopa in Parkinson's disease. Neurology 1996; 46: 475.
59. Kapoor R, Pirtosek Z, Frankel JP, Stern GM, Lees AJ, Bottomley JM et al. Treatment of Parkinson's disease with a novel dopamine D2 agonist SK&F 101468. Lancet 1989; 2: 1.445-1.446.
60. Vidailhet MJ, Bonnet AM, Belal S, Dubois B, Marle C, Agid Y. Ropinirole without levodopa in Parkinson's disease. Lancet 1996; 1: 316-317.
61. Kleendorfer B, Stern GM, Lees AJ, Bottomley JM, Sree-Haran N. Ropinirole (SK and F 101468) in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1991; 54: 938.
62. Burn DJ, Anderson T, Bottomley J, Haran S, Brooks DJ. Treatment of Parkinson's disease with a selective dopamine D2 agonist, ropinirole, as adjunct therapy. Neurology 1991; 41 (Supl 1): 399.